A Study of LY3006072 in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | July 2012 |
| End Date: | January 2013 |
| Contact: | There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or |
| Phone: | 1-317-615-4559 |
A Single Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3006072 in Healthy Subjects
The purpose of this study is to evaluate how safe LY3006072 (study drug) is and whether it
causes any side effects. The study will also measure how much of the study drug gets into
the blood stream and how long it takes the body to get rid of the study drug. The study drug
will be given in the morning or evening with or without a meal.
This is the first time that this study drug is being given to humans. This study is for
research purposes only and is not intended to treat any medical condition.
This study has two parts:
Part A - single ascending dose of LY3006072 administered to healthy participants in 3 of 4
study periods (placebo in 1 of 4 periods).
Part B - morning and evening doses of LY3006072 given to healthy participants in fed and
fasted states in 2 or 3 of 3 study periods (placebo in 1 of 3 periods for some
participants).
Inclusion Criteria:
- Overtly healthy males or females, as determined by medical history and physical
examination
- Male participants with a partner of childbearing potential must agree to use barrier
protection during sexual intercourse while in the study and for 3 months after the
last dose of study drug
- Women must not be pregnant or nursing and must be of non-childbearing potential, due
to either surgical sterilization or menopause
- Body mass index between 19.0 and 30.0 kilograms per square meter (kg/m^2), inclusive
We found this trial at
1
site
Click here to add this to my saved trials
